Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Normal nervous system function and nerve conduction*
CellGenics cGMP manufacturing facility maintains these standards across its full peptide catalog
Published 2012 Jun 22
US$ 27.60
US$ 24.17
US$ 22.46
